OXUR — Oxurion NV Share Price
Last trade - 00:00- €0.60m
- €12.39m
- €0.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -8770.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 3.95 | 2.08 | 1.13 | 0.59 | 0.26 | 1 | n/a | -45.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.
Directors
- Patrik De Haes NEC
- Tom Graney CEO
- Julie Binon CHO
- Alan Stitt CSO
- Kathleen Paisley GCN
- Michael Dillen EXB
- Grace Chang EXB
- Andy De Deene EXB
- David Guyer NED (61)
- Emmanuele Attout NID (61)
- Thomas Clay NID
- Adrienne Graves NID
- Philippe Vlerick NID (65)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- May 30th, 2006
- Public Since
- July 7th, 2006
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 2,002,550
- Address
- Gaston Geenslaan 1, LEUVEN (LOUVAIN), 3001
- Web
- https://www.oxurion.com
- Phone
- +32 16751310
- Auditors
- PwC Bedrijfsrevisoren BV/Reviseurs d’Entreprises SRL
Upcoming Events for OXUR
Similar to OXUR
argenx SE
Euronext - Brussels
Celyad Oncology SA
Euronext - Brussels
Sequana Medical NV
Euronext - Brussels
FAQ
As of Today at 21:31 UTC, shares in Oxurion NV are trading at €0.30. This share price information is delayed by 15 minutes.
Shares in Oxurion NV last closed at €0.30 and the price had moved by -96.68% over the past 365 days. In terms of relative price strength the Oxurion NV share price has underperformed the FTSE Global All Cap Index by -96.98% over the past year.
The overall consensus recommendation for Oxurion NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOxurion NV does not currently pay a dividend.
Oxurion NV does not currently pay a dividend.
Oxurion NV does not currently pay a dividend.
To buy shares in Oxurion NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.30, shares in Oxurion NV had a market capitalisation of €0.60m.
Here are the trading details for Oxurion NV:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: OXUR
Based on an overall assessment of its quality, value and momentum Oxurion NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oxurion NV is €0.30. That is 0.33% above the last closing price of €0.30.
Analysts covering Oxurion NV currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxurion NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -69.65%.
As of the last closing price of €0.30, shares in Oxurion NV were trading -69.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oxurion NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oxurion NV's management team is headed by:
- Patrik De Haes - NEC
- Tom Graney - CEO
- Julie Binon - CHO
- Alan Stitt - CSO
- Kathleen Paisley - GCN
- Michael Dillen - EXB
- Grace Chang - EXB
- Andy De Deene - EXB
- David Guyer - NED
- Emmanuele Attout - NID
- Thomas Clay - NID
- Adrienne Graves - NID
- Philippe Vlerick - NID